IP Library Granted Patent US 9,149,329
Granted Patent B2
US 9,149,329 · App. 14/076,008 · Granted Oct 6, 2015

Glucose alteration methods

Inventors: Bobak Robert Azamian (Newport Coast, CA); Jonathan Allen Coe (Menlo Park, CA); Scott Bradley Vafai (Boston, MA)
Assignee: Metavention, Inc.
A61B18/1492A61B17/00A61B17/00234A61B17/32A61B17/320068A61B18/02A61B18/04A61B18/06A61B18/18A61B18/1815A61B18/20A61K31/045A61K31/05A61K31/395A61K33/30A61K45/06A61M5/14A61N5/00A61N7/00A61B18/24A61B2017/00318A61B2018/0022A61B2018/00023A61B2018/00214A61B2018/00404A61B2018/00434A61B2018/00529A61B2018/00577A61B2018/00791A61B2018/00839A61B2018/0212A61B2018/048A61B2018/1861A61N7/022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,149,329
App. No.
14/076,008
Filed
Nov 8, 2013
Granted
Oct 6, 2015
Kind
B2
Art Unit
3739
USPC
606/41
Abstract

According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.

Claims (29)

1. A method of altering glucose levels, the method comprising:

inserting a cryoablation catheter into a vasculature of a subject,

wherein said cryoablation catheter comprises a distal end,

advancing the distal end of the cryoablation catheter to a location within a portion of a common hepatic artery of the vasculature; and

ablating one or more nerves surrounding the portion of the common hepatic artery using the cryoablation catheter to decrease a glucose level within the subject.

2. The method of claim 1 , wherein the cryoablation catheter comprises a reservoir configured to hold a cooling fluid.

3. The method of claim 1 , wherein the distal end of the cryoablation catheter comprises a balloon.

4. The method of claim 2 , wherein the reservoir comprises a cryochamber.

5. The method of claim 2 , wherein the cooling fluid comprises liquid nitrogen.

6. The method of claim 2 , wherein the cryoablation catheter further comprises a feed line for delivering the cooling fluid to the distal end of the cryoablation catheter and a return line for returning spent cooling fluid to the reservoir.

7. The method of claim 2 , wherein the cooling fluid is configured to reach a temperature of less than 75 degrees Celsius below zero.

8. The method of claim 2 , wherein the cryoablation catheter comprises one or more internal lumens in fluid communication with a proximal opening at a proximal end of the cryoablation catheter, and wherein the proximal opening is in fluid communication with the reservoir.

9. A method of altering glucose levels, the method comprising:

positioning a neuromodulation device adjacent to a hepatic plexus of a subject; and

disrupting neural communication along one or more nerves of the hepatic plexus using the neuromodulation device to decrease a glucose level in the subject,

wherein the neuromodulation device comprises a cryotherapy device.

10. The method of claim 9 , wherein said positioning the neuromodulation device comprises intravascularly advancing a distal end of the neuromodulation device to a location within a hepatic artery of the subject and wherein said disrupting comprises intravascularly modulating the one or more nerves.

11. The method of claim 9 , wherein said positioning the neuromodulation device comprises passing the neuromodulation device transluminally to an extravascular space and wherein said disrupting comprises extravascularly modulating the one or more nerves.

12. The method of claim 9 , wherein said disrupting further comprises delivering energy to the one or more nerves sufficient to modulate the one or more nerves.

13. The method of claim 9 , wherein said disrupting further comprises delivering a chemoablative agent to the one or more nerves.

14. The method of claim 9 , wherein said disrupting further comprises physically severing the one or more nerves.

15. A method of altering glucose levels, the method comprising:

positioning a neuromodulation device adjacent to a hepatic plexus of a subject and disrupting neural communication along one or more sympathetic nerve fibers of the hepatic plexus of the subject sufficient to decrease a glucose level within the subject,

wherein said disrupting comprises delivering at least one of a cooling fluid or steam using the neuromodulation device.

16. The method of claim 15 , wherein a distal end of the neuromodulation device comprises a steam outlet configured to deliver steam generated by the neuromodulation device to ablate said one or more sympathetic nerve fibers.

17. The method of claim 15 , wherein said positioning the neuromodulation device comprises intravascularly advancing a distal end of the neuromodulation device to a location within a hepatic artery of the subject.

18. The method of claim 15 , wherein the cooling fluid is configured to reach a temperature of less than 75 degrees Celsius below zero.

19. The method of claim 15 , wherein said disrupting comprises delivering a cooling fluid adapted to ablate the one or more nerves.

20. The method of claim 15 , wherein said disrupting comprises delivering steam to the one or more nerves.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2023
From: METAVENTION, INC.
To: MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANY
Reel/Frame 064987/0161 →
RELEASE OF SECURITY INTEREST Recorded Aug 22, 2023
From: CUSTOMERS BANK (SUCCESSOR IN INTEREST TO SIGNATURE BANK)
To: METAVENTION, INC.
Reel/Frame 064670/0039 →
SECURITY INTEREST Recorded Jan 11, 2023
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 062349/0859 →
SECURITY INTEREST Recorded Oct 31, 2022
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 061602/0249 →
SECURITY INTEREST Recorded Jun 29, 2022
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 060358/0417 →
SECURITY INTEREST Recorded Dec 20, 2021
From: METAVENTION, INC.
To: SIGNATURE BANK
Reel/Frame 058433/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2013
From: AZAMIAN, BOBAK ROBERT; COE, JONATHAN ALLEN; VAFAI, SCOTT BRADLEY
To: METAVENTION, INC.
Reel/Frame 031578/0683 →
Continuity (4)
Continuation 13789509 · Mar 7, 2013
Continuation PCTUS2012068630 · Dec 7, 2012
Provisional Application 61568843 · Dec 9, 2011
Related Publication 20140066883A1 · Mar 6, 2014